Literature DB >> 12921904

Inflammatory processes in Alzheimer's disease.

Edith G McGeer1, Patrick L McGeer.   

Abstract

Neuroinflammation is a characteristic of pathologically affected tissue in several neurodegenerative disorders. These changes are particularly observed in affected brain areas of Alzheimer's disease (AD) cases. They include an accumulation of large numbers of activated microglia and astrocytes as well as small numbers of T-cells, mostly adhering to postcapillary venules. Accompanying biochemical alterations include the appearance or up-regulation of numerous molecules characteristic of inflammation and free radical attack. Particularly important may be the complement proteins, acute phase reactants and inflammatory cytokines. These brain phenomena combined with epidemiological evidence of a protective effect of antiinflammatory agents suggest that such agents may have a role to play in treating the disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12921904     DOI: 10.1016/S0278-5846(03)00124-6

Source DB:  PubMed          Journal:  Prog Neuropsychopharmacol Biol Psychiatry        ISSN: 0278-5846            Impact factor:   5.067


  137 in total

1.  Evodiamine improves congnitive abilities in SAMP8 and APP(swe)/PS1(ΔE9) transgenic mouse models of Alzheimer's disease.

Authors:  Shu-min Yuan; Kai Gao; Dong-mei Wang; Xiong-zhi Quan; Jiang-ning Liu; Chun-mei Ma; Chuan Qin; Lian-feng Zhang
Journal:  Acta Pharmacol Sin       Date:  2011-01-31       Impact factor: 6.150

2.  Drug discovery for Alzheimer's disease: the end of the beginning.

Authors:  Lorenzo M Refolo; Howard M Fillit
Journal:  J Mol Neurosci       Date:  2004       Impact factor: 3.444

Review 3.  Chemical genetics of neuroinflammation: natural and synthetic compounds as microglial inhibitors.

Authors:  Kyoungho Suk; Jiyeon Ock
Journal:  Inflammopharmacology       Date:  2011-12-22       Impact factor: 4.473

Review 4.  Multi-dimensional mass spectrometry-based shotgun lipidomics and the altered lipids at the mild cognitive impairment stage of Alzheimer's disease.

Authors:  Xianlin Han
Journal:  Biochim Biophys Acta       Date:  2010-02-01

5.  The interaction of amyloid β and the receptor for advanced glycation endproducts induces matrix metalloproteinase-2 expression in brain endothelial cells.

Authors:  Huan Du; Pengtao Li; Jun Wang; Xuemei Qing; Weihong Li
Journal:  Cell Mol Neurobiol       Date:  2011-08-12       Impact factor: 5.046

6.  Ablation of TNF-RI/RII expression in Alzheimer's disease mice leads to an unexpected enhancement of pathology: implications for chronic pan-TNF-α suppressive therapeutic strategies in the brain.

Authors:  Sara L Montgomery; Michael A Mastrangelo; Diala Habib; Wade C Narrow; Sara A Knowlden; Terry W Wright; William J Bowers
Journal:  Am J Pathol       Date:  2011-08-09       Impact factor: 4.307

Review 7.  The neuroprotective effects of cocoa flavanol and its influence on cognitive performance.

Authors:  Astrid Nehlig
Journal:  Br J Clin Pharmacol       Date:  2013-03       Impact factor: 4.335

Review 8.  Role of cytosolic calcium-dependent phospholipase A2 in Alzheimer's disease pathogenesis.

Authors:  M T Gentile; M G Reccia; P P Sorrentino; E Vitale; G Sorrentino; A A Puca; L Colucci-D'Amato
Journal:  Mol Neurobiol       Date:  2012-05-31       Impact factor: 5.590

Review 9.  Potential mechanisms contributing to sulfatide depletion at the earliest clinically recognizable stage of Alzheimer's disease: a tale of shotgun lipidomics.

Authors:  Xianlin Han
Journal:  J Neurochem       Date:  2007-11       Impact factor: 5.372

10.  Cognitive dysfunction with aging and the role of inflammation.

Authors:  Arthur A Simen; Kelly A Bordner; Mark P Martin; Lawrence A Moy; Lisa C Barry
Journal:  Ther Adv Chronic Dis       Date:  2011-05       Impact factor: 5.091

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.